Skip to content
Study details
Enrolling now

Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma

City of Hope Medical Center
NCT IDNCT05800405ClinicalTrials.gov data as of Apr 2026
Phase

EARLY_PHASE1

Target enrollment

9

Study length

about 2.5 years

Ages

18+

Locations

1 site in CA

What this study is about

This trial is testing if giving radiation therapy before a type of immunotherapy called CAR T-cell infusion can help people with relapsed or refractory large B-cell lymphoma. The goal is to see if this bridging therapy improves treatment outcomes and reduces side effects.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Chimeric Antigen Receptor T-Cell Therapy
  • 2.Receive External Beam Radiation Therapy
  • 3.Undergo Biospecimen Collection
  • +3 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

cell therapy

Endpoints

Secondary: Complete response rate, Incidence of AEs, Local control, Objective response rate, Overall survival, Progression free survival

Procedures

diagnostic, imaging, radiation, therapy